Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May 12:(75):e50326.
doi: 10.3791/50326.

Direct intraventricular delivery of drugs to the rodent central nervous system

Affiliations

Direct intraventricular delivery of drugs to the rodent central nervous system

Sarah L DeVos et al. J Vis Exp. .

Abstract

Due to an inability to cross the blood brain barrier, certain drugs need to be directly delivered into the central nervous system (CNS). Our lab focuses specifically on antisense oligonucleotides (ASOs), though the techniques shown in the video here can also be used to deliver a plethora of other drugs to the CNS. Antisense oligonucleotides (ASOs) have the capability to knockdown sequence-specific targets (1) as well as shift isoform ratios of specific genes (2). To achieve widespread gene knockdown or splicing in the CNS of mice, the ASOs can be delivered into the brain using two separate routes of administration, both of which we demonstrate in the video. The first uses Alzet osmotic pumps, connected to a catheter that is surgically implanted into the lateral ventricle. This allows the ASOs to be continuously infused into the CNS for a designated period of time. The second involves a single bolus injection of a high concentration of ASO into the right lateral ventricle. Both methods use the mouse cerebral ventricular system to deliver the ASO to the entire brain and spinal cord, though depending on the needs of the study, one method may be preferred over the other.

PubMed Disclaimer

References

    1. Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Annual Review of Pharmacology and Toxicology. 1996;36:107–129. - PubMed
    1. Sazani P, Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. The Journal of Clinical Investigation. 2003;112(4):481–486. - PMC - PubMed
    1. Taylor JP, Hardy J, Fischbeck KH. Toxic Proteins in Neurodegenerative Disease. Science. 2002;296(5575):1991–1995. - PubMed
    1. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nature Medicine. 2004;10:S10–S17. - PubMed
    1. Miller TM, Smith RA, Kordasiewicz H, Kaspar BK. Gene-Targeted Therapies for the Central Nervous System. Archives of Neurology. 2008;65(4):447–451. - PubMed

Publication types

MeSH terms

Substances